Eribulin mesylate.

11:34 EST 21st December 2014 | BioPortfolio

Summary of "Eribulin mesylate."

Eribulin mesylate (Halaven; Eisai) - a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics - was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.

Affiliation

Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.

Journal Details

This article was published in the following journal.

Name: Nature reviews. Drug discovery
ISSN: 1474-1784
Pages: 173-4

Links

PubMed Articles [41 Associated PubMed Articles listed on BioPortfolio]

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells.

Treatment of advanced ovarian cancer involves platinum-based chemotherapy. However, chemoresistance is a major obstacle. Cancer stem cells (CSCs) are thought to be one of the causes of chemoresistance...

Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer.

Following the demonstrated efficacy and safety of eribulin mesylate in heavily pretreated patients with metastatic breast cancer, an exploratory analysis was performed to investigate the effect of age...

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient subgroups, previously treated with an anthracy...

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.

ABSTRACT  Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin mesylate is a novel antimicr...

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease. Objectives: This m...

Clinical Trials [334 Associated Clinical Trials listed on BioPortfolio]

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refrac...

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval a...

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

This phase I/IB trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone...

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

This phase I trial is studying the side effects and best dose of eribulin mesylate and gemcitabine hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs us...

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical ben...

Medical and Biotech [MESH] Definitions

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Search BioPortfolio:
Loading
Advertisement
Advertisement